ALVO

Handel nachbörslich: 10.50

Alvotech (ALVO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Alvotech Stock (ALVO) Company Profile

Healthcare (1149)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ALVO's Discussions on Twitter

Vergleichen Sie ALVO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALVO Alvotech	10.50	2.40B	391.87M	-441.45M	-301.21M	-1.85
ZTS Zoetis Inc	154.92	69.45B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.40	48.49B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	13.71	47.40B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.89	20.19B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	299.68	13.84B	2.99B	1.21B	1.13B	25.06

Alvotech Stock (ALVO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-14	Eingeleitet	UBS	Buy
2024-01-29	Hochstufung	Barclays	Equal Weight → Overweight
2023-10-20	Hochstufung	Citigroup	Sell → Neutral
2023-09-21	Eingeleitet	Barclays	Equal Weight
2022-09-07	Eingeleitet	Morgan Stanley	Equal-Weight
2022-09-06	Herabstufung	Citigroup	Buy → Sell
2022-07-26	Eingeleitet	Citigroup	Buy

Alle ansehen

Alvotech Aktie (ALVO) Neueste Nachrichten

Finanzdaten der Alvotech-Aktie (ALVO)

Alvotech (ALVO)

Alvotech Stock (ALVO) Company Profile

Vergleichen Sie ALVO mit anderen Aktien

Alvotech Stock (ALVO) Upgrades & Downgrades

Alvotech Aktie (ALVO) Neueste Nachrichten

Alvotech at BofA Securities Healthcare Conference: Strategic Biosimilar Focus By Investing.com - Investing.com India

Alvogen Lux Holdings Acquires 210,000 Shares in Alvotech at ISK 1,277.38 - Nasdaq

Transactions of Managers and Closely Associated Persons - marketscreener.com

Alvotech Raises 2025 Revenue Guidance Amid Strong Performance - TipRanks

Teva, Alvotech receive FDA nod for interchangeability of Selardsdi with Stelara - Drug Store News

Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report - Yahoo Finance

Alvotech CEO Acquires Significant Shareholding, Strengthening Market Confidence - TipRanks

Is Alvotech (ALVO) The Best Stock That Will Bounce Back? - Insider Monkey

Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada - The Manila Times

Alvotech Reports Strong Q1 2025 Earnings Growth - TipRanks

Alvotech earnings beat by $0.32, revenue topped estimates - Investing.com Nigeria

Alvotech sees minimal impact on 2025 product revenues from tariffs - MSN

Transcript : Alvotech, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com

Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday - Benzinga

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT - marketscreener.com

Alvotech Reports Robust Q1 2025 Growth and Strategic Expansions - TipRanks

ACM Research Reports First Quarter 2025 Results - Stock Titan

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm - The Manila Times

Alvotech Q1 2025 Earnings Call Transcript - MarketBeat

Alvotech (NASDAQ:ALVO) Sees Significant Growth in Short Interest - MarketBeat

Alvotech shares surge 6.6% as Q1 results top estimates By Investing.com - Investing.com Nigeria

Alvotech shares surge 6.6% as Q1 results top estimates - Investing.com

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update - The Manila Times

Alvotech Anticipates Minimal Impact from Potential U.S. Tariffs on Imported Pharmaceuticals in 2025 - Nasdaq

Alvotech Sees Minimal Impact On 2025 Revenues From U.S. Tariffs - marketscreener.com

Alvotech : Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - marketscreener.com

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025 - The Manila Times

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 - Yahoo Home

Teva, Alvotech get FDA nod for Johnson & Johnson biosimilar - MSN

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab - insights.citeline.com

FDA approves Teva-Alvotech biosimilar Selarsdi for multiple conditions - World Pharmaceutical Frontiers

Alvotech SA expected to post a loss of 11 cents a shareEarnings Preview - TradingView

FDA Approves SELARSDI from Alvotech (ALVO) as Interchangeable Bi - GuruFocus

Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? - Benzinga

Teva, Alvotech announce FDA approval of interchangeability for SELARSDI - TipRanks

US FDA Approves Alvotech's Selarsdi for Full Interchangeability with J&J's Stelara - marketscreener.com

Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Nigeria

Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com Australia

Teva, Alvotech: FDA approves interchangeability for SELARSDI with Stelara - TipRanks

Alvotech’s SELARSDI Gains FDA Approval for Interchangeability with Stelara - TipRanks

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) | TEVA Stock News - GuruFocus

Teva, Alvotech Get FDA Approval for Selarsdi's Interchangeablity With Stelara - marketscreener.com

Teva and Alvotech Announce FDA Approval of - GlobeNewswire

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) - finanzen.ch

FDA Grants Full Interchangeability to New Stelara Biosimilar for Multiple Autoimmune Conditions - Stock Titan

FDA Approval Boosts Alvotech's (ALVO) SELARSDI as Interchangeabl - GuruFocus

Alvotech to Announce Q1 2025 Financial Results on May 7, 2025, with Conference Call on May 8, 2025 - Nasdaq

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - The Manila Times

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14 - marketscreener.com

REG-Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) - TradingView

Finanzdaten der Alvotech-Aktie (ALVO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ALVO